Tempus AI (NASDAQ:TEM) CFO James William Rogers Sells 10,853 Shares

Tempus AI, Inc. (NASDAQ:TEM) CFO James William Rogers sold 10,853 shares of the company’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $44.07, for a total value of $478,291.71. Following the completion of the sale, the chief financial officer owned 126,395 shares in the company, valued at approximately $5,570,227.65. This represents a 7.91% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Tempus AI Price Performance

Shares of NASDAQ TEM opened at $46.49 on Friday. The business’s 50 day moving average price is $49.02 and its 200 day moving average price is $59.39. The firm has a market cap of $8.35 billion, a P/E ratio of -27.03 and a beta of 3.99. Tempus AI, Inc. has a 52 week low of $41.73 and a 52 week high of $104.32. The company has a quick ratio of 3.15, a current ratio of 3.31 and a debt-to-equity ratio of 2.96.

Tempus AI (NASDAQ:TEM) last issued its earnings results on Tuesday, May 5th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.08. Tempus AI had a negative return on equity of 53.83% and a negative net margin of 22.20%.The firm had revenue of $348.12 million for the quarter, compared to analyst estimates of $345.44 million. During the same quarter in the prior year, the firm earned ($0.24) earnings per share. Tempus AI’s revenue for the quarter was up 36.1% on a year-over-year basis. On average, sell-side analysts expect that Tempus AI, Inc. will post -1.35 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the business. Victory Capital Management Inc. raised its stake in shares of Tempus AI by 1.5% during the 3rd quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock worth $894,000 after buying an additional 162 shares during the period. US Bancorp DE raised its stake in shares of Tempus AI by 6.6% during the 3rd quarter. US Bancorp DE now owns 2,848 shares of the company’s stock worth $230,000 after buying an additional 176 shares during the period. Legacy Bridge LLC raised its stake in Tempus AI by 1.6% in the 4th quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock valued at $733,000 after purchasing an additional 193 shares during the last quarter. Truist Financial Corp raised its stake in Tempus AI by 5.8% in the 4th quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after purchasing an additional 194 shares during the last quarter. Finally, Farther Finance Advisors LLC raised its stake in Tempus AI by 3.5% in the 4th quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock valued at $377,000 after purchasing an additional 219 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

TEM has been the subject of a number of analyst reports. Jefferies Financial Group initiated coverage on Tempus AI in a report on Monday, April 13th. They issued an “underperform” rating and a $35.00 price target for the company. JPMorgan Chase & Co. decreased their price target on Tempus AI from $80.00 to $60.00 and set a “neutral” rating for the company in a report on Wednesday, February 25th. Guggenheim decreased their price target on Tempus AI from $95.00 to $60.00 and set a “buy” rating for the company in a report on Monday, March 30th. Stifel Nicolaus set a $60.00 price target on Tempus AI in a report on Wednesday, February 25th. Finally, TD Cowen boosted their price target on Tempus AI from $65.00 to $68.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $68.64.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.